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Background. Medication classes, polypharmacy, hazardous alcohol and illicit substance abuse 62 
may exhibit stronger associations with serious falls among persons living with HIV (PLWH) than 63 
with uninfected comparators. We investigated whether these associations differed by HIV 64 
status. 65 
Setting. Veterans Aging Cohort Study 66 
Methods. We employed a nested case-control design. Cases (N=13,530) were those who fell. 67 
Falls were identified by external cause of injury codes and a machine learning algorithm applied 68 
to radiology reports. These were matched to controls (N=67,060) by age, race, sex, HIV status, 69 
duration of observation, and baseline date. Risk factors included medication classes, count of 70 
unique non-antiretroviral (non-ART) medications, and hazardous alcohol and illicit substance 71 
use. We used unconditional logistic regression to evaluate associations.   72 
Results. Among PLWH, benzodiazepines (odds ratio (OR) 1.24; 95% confidence interval (CI) 73 
1.08, 1.40) and muscle relaxants (OR 1.29; 95% CI 1.08, 1.46) were associated with serious 74 
falls but not among uninfected (p>0.05). In both groups, key risk factors included non-ART 75 
medications (per five medications) (OR 1.20, 95% CI 1.17, 1.23), illicit substance use/abuse 76 
(OR 1.44; 95% CI 1.34, 1.55), hazardous alcohol use (OR 1.30; 95% CI 1.23, 1.37), and an 77 
opioid prescription (OR 1.35; 95% CI 1.29, 1.41). 78 
Conclusion. Benzodiazepines and muscle relaxants were associated with serious falls among 79 
PLWH. Non-ART medication count, hazardous alcohol and illicit substance use, and opioid 80 
prescriptions were associated with serious falls in both groups. Prevention of serious falls 81 
should focus on reducing specific classes and absolute number of medications and both alcohol 82 
and illicit substance use.   83 




Falls are associated with fractures,1 traumatic brain injury,1 disability,2 and death3 and are a 86 
growing concern for people aging with HIV.4-8 Of particular importance are falls that cause a 87 
patient to seek health care (serious falls). Previous research has provided conflicting evidence 88 
about fall risk factors among persons living with HIV (PLWH) and whether or not these risk 89 
factors differ for PLWH and uninfected comparators.  90 
Established risk factors for falls among older adults include medication classes (cardiovascular 91 
medications,9 psychotropics,10 opioids, anticonvulsants, and proton pump inhibitors11) and 92 
polypharmacy. Among PLWH, Erlandson and colleagues found that cardiovascular medications, 93 
psychotropics, and multiple comorbidities were associated with increased risk of falls, but this 94 
study did not include an uninfected comparison group.4 Another study that included uninfected 95 
individuals found that hepatitis C virus infection (HCV), female sex, obesity, smoking and clinical 96 
imbalance symptoms were associated with falls, but that age, HIV serostatus, and other 97 
comorbidities were not.5 Others suggest that comorbidity count7 and the number of medications 98 
prescribed11,12 are associated with fall risk among PLWH, but neither of these studies provided 99 
comparisons with uninfected individuals.  100 
Of particular importance to our work, hazardous alcohol and illicit substance use have been 101 
inconsistently associated with falls among PLWH. Sharma and colleagues found that heavy 102 
alcohol use was associated with recurrent but not with single falls.6 Erlandson and colleagues 103 
found no association between alcohol use and falls4,5 but reported that current illicit substance 104 
use was associated with a lower risk of falling.4 This association may have been confounded by 105 
individuals who stopped using substances due to chronic illness.13 Sharma and colleagues 106 
found that marijuana use – but not  use of heroin, cocaine, or crack -- was independently 107 
associated with falls.6  108 
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Also of note, PLWH experience polypharmacy a decade earlier than uninfected individuals.14 109 
They are more susceptible to harm from polypharmacy due to increased physiologic frailty 15 110 
and persistent use of alcohol14 and other substances into older age.16,17 Therefore, alcohol, illicit 111 
substance use and polypharmacy may play a more important role in serious falls among PLWH 112 
than among uninfected comparators. 113 
 Most prior studies have been limited in size and regional variation, and few have compared 114 
risks among PLWH and uninfected individuals. In this large national study, we explore the 115 
association between falls and specific medications, polypharmacy, harmful alcohol use, and 116 
substance use disorder using data from the Veterans Aging Cohort Study (VACS). We 117 
investigate whether these associations differ by HIV status and identify the relative importance 118 
of fall risk factors in this population. 119 
METHODS 120 
We used a nested case-control study design to explore these questions.  121 
Sample 122 
VACS is a national, prospective, observational cohort that includes all Veterans diagnosed with 123 
HIV within the Veterans Health Administration (VA) and demographically matched uninfected 124 
comparators.18 We included data from 10/01/2007 through 09/20/2015. We used 10/01/2007 as 125 
the lower cutoff because we wanted to include Alcohol Use Disorders Identification Test – 126 
Consumption (AUDIT-C) as our measure of hazardous alcohol use. AUDIT-C was not 127 
consistently available in the VA electronic health record before 10/01/2007. We used 128 
09/30/2015 as the upper cut off because this was the last date through which we had access to 129 
radiology reports and could thus use our machine learning algorithm to identify serious falls from 130 
that source. From 133,658 individuals who received care between 10/01/2007 and 09/30/2015, 131 
we established a base cohort of 115,426 individuals who had at least one AUDIT-C measure 132 
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available. We defined baseline as the date of the first AUDIT-C that occurred after 10/01/2007, 133 
with a concurrent outpatient prescription within 30 days of the AUDIT-C, at least 12 months after 134 
VACS enrollment. We excluded individuals (Figure 1): a) with VACS Index score >100 at 135 
baseline (N=244); b) who seroconverted (N=327); or c) who had a serious fall on or before 136 
baseline (N=16,395). We identified cases (those with a serious fall: N= 13,530) and matched 137 
them to at-risk individuals by age within one year, race, sex, HIV status, duration of observation 138 
since baseline, and baseline date within one year. We matched 98.6% of individuals who fell to 139 
5 controls each.  140 
Serious falls 141 
Cases were the first serious fall experienced by participants. We identified serious falls using 142 
International Classification of Disease (ICD) codes and radiology reports. We used ICD-9 143 
external cause of injury codes (Ecodes): E880.X, E881.X, E884.X, E885.9, E886.9, E888.X.19 144 
As Ecodes are specific but not sensitive for serious falls, we also used a machine learning 145 
algorithm that identified serious falls in radiology reports.20 This algorithm has been validated 146 
(positive predictive value: 93%; sensitivity: 95%; F measure (the harmonic mean of positive 147 
predictive value and sensitivity): 94%; and accuracy: 99%).20 148 
Primary predictors 149 
Primary predictors were specific medication classes, count of unique non-antiretroviral (ART) 150 
outpatient medications, hazardous alcohol use, and illicit substance use. Active medications 151 
were identified in the window 3 to 45 days before the serious fall or match date. Medication 152 
classes (Appendix) were identified using VHA fill-refill data and included: mental health 153 
medications (antipsychotics, atypical antidepressants, monoamine oxidase inhibitors [MAOIs], 154 
selective serotonin reuptake inhibitors [SSRIs], serotonin and norepinephrine reuptake inhibitors 155 
[SNRIs], tricyclic antidepressants [TCAs]), central nervous system (CNS)-active medications 156 
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(opioids, benzodiazepines, muscle relaxants, anticonvulsants, and antihistamines), 157 
cardiovascular medications (antiarrhythmics, antihypertensives, antithrombotics, nitrates), 158 
hypoglycemics, and proton pump inhibitors. We included a count of active non-ART medications 159 
in the 3-45 day window prior to the fall or match date. Hazardous alcohol use was defined as 160 
AUDIT-C summated score >3 for women and >4 for men.21 We used the AUDIT-C score closest 161 
to serious fall date (or match date for controls) up to one year prior to that date. We identified 162 
illicit substance use from ICD9 codes prior to baseline (ICD9 codes 292.0, 292.11, 292.12, 163 
304.XX, 305.XX).  164 
Comorbidities, identified using ICD9 codes (one inpatient or two outpatient), included: 165 
osteoarthritis, hypertension, heart failure, coronary artery disease, stroke, transient ischemic 166 
attack, dementia (inpatient only), chronic obstructive pulmonary disease (COPD), asthma, 167 
anxiety, bipolar disorder, major depression, mild depression, psychosis, and schizophrenia. 168 
Hepatitis C virus (HCV) infection status was identified by detectable plasma HCV-RNA, positive 169 
antibody test, or documented diagnosis. To adjust for comorbid disease severity, we used the 170 
VACS Index 2.0 score closest to serious fall or match date. The  Index uses demographic 171 
information and routinely assessed laboratory measures associated with all-cause mortality: 172 
age, CD4 count, HIV-1RNA, hemoglobin, FIB-4 ((age[years]xAST[IU/L]/platelet count[expressed 173 
as platelets x 109/L] x (ALT1/2[IU/L])), eGFR ((186.3 x serum creatinine-1.154) x (age-0.203) x (1.21 if 174 
black)), hepatitis C status, body mass index (BMI), albumin, and white blood cell (WBC) count.22 175 
The VACS Index has been validated in PLWH and in uninfected populations.22,23 We did not 176 
include smoking as the VACS Index accounts for most of the upstream effects of smoking. 177 
Ethics 178 
VACS was approved by the Institutional Review Boards of VA Connecticut Healthcare System 179 
and Yale University. It has been granted a waiver of informed consent and is HIPAA 180 
compliant.18  181 
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Statistical methods 182 
Analyses began with a comparison of the distributions of primary predictors between cases and 183 
controls within strata defined by HIV status. Continuous variables were compared with a t-test 184 
and categorical with a chi-square statistic.  185 
Multivariable unconditional logistic regression24 was used to evaluate the associations between 186 
primary predictors of interest and occurrence of a serious fall with adjustment for covariates. 187 
The four matching variables with potential for confounding were age, race, sex, and HIV status. 188 
Each of these four were removed one at a time to detect substantive change (>10% on the log-189 
odds scale) in the associations of primary interest. Because only the removal of HIV resulted in 190 
such a change, HIV was the only matching variable retained in the final multivariable model. We 191 
subsequently explored multivariable models stratified by HIV status to identify potential 192 
differential associations between predictors and serious falls. We fit the same multivariable 193 
model, adding HIV and interaction terms, to the entire cohort to identify significant interactions 194 
using estimate statements.  195 
Among PLWH, we explored the association between ART and serious falls. Among those on 196 
ART, we explored associations among ART classes (protease inhibitors (PIs), 197 
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse 198 
transcriptase inhibitors (NNRTIs), and integrase inhibitors (INSTIs) and serious falls. Finally, we 199 
included all individual ART medications in one analysis and then limited our model to include 200 
those with the most signal (ritonavir, tenofovir, raltegravir, and efavirenz).  201 
The percent of missing data ranged from 0% to 13%. BMI and laboratory data had the highest 202 
rates of missingness (13% for PLWH and 9% for uninfected). We assumed that the missing 203 
values were missing at random and employed multiple imputation using a fully conditional 204 
specification as implemented in the SAS procedure MI.25 The imputation model included serious 205 
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falls and all aforementioned covariates. Models were fit to each of the five imputed datasets and 206 
the resulting coefficients were used to derive the reported results. This was implemented using 207 
the SAS procedure MIANALYZE which combines the imputation-specific coefficients based on 208 
Rubin’s Rules.25 To compare the relative importance of the variables that we included in our 209 
models, We used the t- value obtained from logistic regression to compare the relative 210 
importance of the variables that we included in our models. All analyses were performed using 211 
SAS Version 9.4 with statistical significance defined as a two-tailed p-value<0.05. 212 
Role of the funding source 213 
The funding sources had no role in study design; in the collection, analysis, and interpretation of 214 
data; in the writing of the report; or in the decision to submit the paper for publication. 215 
RESULTS 216 
Our analysis included 80,590 Veterans; 23,252 (29%) were PLWH. Median follow-up time was 217 
2.3 years (IQR 1.0-4.0 years). We observed 13,530 serious falls (3919 among PLWH and 9611 218 
among uninfected). The mean age at time of serious fall was 57 years for PLWH and 58 for 219 
uninfected (p<0.001).  220 
The sample was primarily black (49%) and male (96%). Baseline characteristics of cases and 221 
controls within strata defined by HIV status are included in Table 1. Among PLWH, there were 222 
no differences in BMI between cases or controls. Among PLWH and uninfected comparators, 223 
cases were more likely to take medications from the medication classes of interest with three 224 
exceptions. First, among uninfected individuals, controls were far more likely to have a 225 
prescription for an antithrombotic (66% vs 8%, p<0.001). Second, among PLWH, controls were 226 
somewhat more likely to have a prescription for a benzodiazepine (14% vs 13%, p<0.001). 227 
Third, there was no difference between cases and controls for prescriptions for MAO inhibitors 228 
(0.03% and 0.01%, p=0.45). Among PLWH and uninfected, cases had a higher mean 229 
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medication count than controls. Prevalence of substance use and comorbidities was higher 230 
among cases regardless of HIV status. Among PLWH, cases were less likely to take NRTI (69% 231 
vs 73%, p=0.01), or NNRTI (33% vs 37%, p<0.001), but were more likely to take an integrase 232 
inhibitor (14% vs 12%, p=0.01). Controls were more likely to take epivir (3TC) (24% vs 22% 233 
p=0.02).  234 
In models stratified by HIV status, receipt of benzodiazepines (PLWH odds ratio (OR) 1.25; 95% 235 
confidence interval (CI) 1.11, 1.39; uninfected OR 1.02; 95% CI 0.95, 1.10; p=0.002) or muscle 236 
relaxants (PLWH OR 1.32; 95% CI 1.15, 1.41; uninfected OR 1.04; 95% CI 0.96, 1.12; p=0.001) 237 
was associated with serious falls among PLWH but not among uninfected (Figure 2) (Table 2). 238 
Other covariates strongly associated with serious falls did not differ by HIV status. 239 
In the combined model (Table 2), the most important covariates (listed from highest to lowest  t-240 
value) associated with increased risk of serious fall were count of non-ART medications (per five 241 
medications) (OR 1.19, 95% CI 1.16, 1.22), diagnosis of drug use/abuse (OR 1.36; 95% CI 242 
1.30, 1.42), VACS Index 2.0 (increments of five) (OR 1.06; 95% CI 1.05, 1.06), and hazardous 243 
alcohol use (OR 1.32; 95% CI 1.24, 1.39). Individual medication classes were also associated 244 
with serious falls: opioids (OR 1.34; 95% CI 1.28, 1.41), anticonvulsants (OR 1.32; 95% CI 1.25, 245 
1.39), SSRIs (OR 1.22; 95% CI 1.16, 1.28),  antithrombotics (OR 1.20; 95% CI 1.11, 1.30), 246 
antiarrhythmics (OR 1.32; 95% CI 1.16, 1.50), SNRIs (OR 1.16; 95% CI 1.05, 1.29), and MAOIs 247 
(OR 2.37; 95% CI 1.05, 5.33). 248 
Antihypertensives (OR 0.85; 95% CI 0.81, 0.89) and antipsychotics (OR 0.90; 95% CI 0.85, 249 
0.96) were associated with a lower risk of serious falls, as was ART use (OR 0.85; 95% CI 0.78, 250 
0.92) among PLWH. Neither ART classes; nor individual ART -- specifically ritonavir, tenofovir, 251 




In the largest and most in-depth study of serious falls among PLWH and uninfected 254 
comparators to date, we found that benzodiazepines and muscle relaxants were associated with 255 
serious falls among PLWH but not among uninfected. Other medication classes including 256 
opioids, anticonvulsants, antiarrhythmics, antithrombotics, MAOIs, SSRIs, and SNRIs were 257 
strongly associated with serious falls, but the association did not differ by HIV status. The risk 258 
factors most strongly associated with falls in both groups were the number of medications 259 
prescribed, higher VACS Index 2.0 score, illicit substance use, prescription opioids, 260 
anticonvulsants, and hazardous alcohol use. Among PLWH, ART use was associated with 261 
lower risk of serious falls.  Among those on ART, serious falls were associated with neither ART 262 
class nor individual ART.  263 
Our results highlight the importance of both classes and counts of medications in risk of serious 264 
falls among PLWH. This association is established among older adults26,27 and has been 265 
suggested by other investigators among PLWH.4,12 The stronger association between 266 
benzodiazepines, muscle relaxants and serious falls among PLWH relative to uninfected 267 
comparators is particularly striking. These medications may interact with ART or direct effects of 268 
the virus may increase their impact. For example, midazolam, triazolam, alprazolam and many 269 
of the muscle relaxants are metabolized by CYP3A4.28 Protease inhibitors, particularly ritonavir, 270 
are known inhibitors of this liver enzyme system. Co-administration may increase the 271 
bioavailability of benzodiazepines and muscle relaxants, accentuating the association of these 272 
medications with serious falls.29 HIV is also known to compromise the integrity of the blood brain 273 
barrier.30 This may result in higher concentrations of benzodiazepines and muscle relaxants in 274 
the brain, again increasing risk of serious falls. 275 
Even after adjusting for specific medication classes, illicit substance use/abuse, hazardous 276 
alcohol use, and severity of illness, medication count was the factor most strongly associated 277 
with serious falls in our study. Medication reconciliation, discontinuing medications, changing to 278 
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safer alternative medications, and reducing medications to the lowest effective dose31 are 279 
important interventions to reduce polypharmacy (deprescribing). How to implement this policy in 280 
a largely middle-aged population in care for HIV remains to be explored.32 281 
Most of our findings correlate well with the geriatric literature. The lack of association seen 282 
between benzodiazepines and muscle relaxants and serious falls among uninfected 283 
comparators may be due to the fact that the mean age for uninfected comparators at the time of 284 
fall or match was 58±9 years. This is much younger than the geriatric population which typically 285 
includes individuals 65 years of age or older. It is possible that in younger members of the 286 
general population, these medications may not have the same fall-related impact as in older 287 
adults. Importantly, neither hazardous alcohol nor illicit substance use are targeted in existing 288 
fall prevention efforts such as the CDC’s STEADI program.31 Prior research on falls in the 289 
general population was carried out at a time when continued use of alcohol and illicit 290 
substances was less common in an aging population.33  Our data suggests its importance has 291 
increased in both those aging with and without HIV infection. Efforts to reduce hazardous 292 
alcohol and illicit substance use need to be integrated with the more established interventions of 293 
exercise and balance/strength training to reduce serious falls among PLWH.  294 
This study has strengths and limitations. VACS is the largest cohort of individuals aging with 295 
HIV in North America. We were well-powered to explore serious falls in this population. Because 296 
VACS is an electronic health record (EHR)-based cohort, we had access to a greater range of 297 
clinical variables than other cohorts. We also had access to detailed information on medication 298 
exposure and alcohol use. Our analytic approach ensured that we identified exposures of 299 
interest prior to the outcome, thus reducing the risk of reverse causality. It is important to 300 
remember that we used a nested case-control study for this study. We identified cases (those 301 
who fell) and then matched them to other at-risk individuals as described earlier. Because of this 302 
matching, our sample should reflect those who fell and not PLWH or uninfected individuals more 303 
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generally. Characteristics may therefore differ from what would be expected from VACS as a 304 
whole. 305 
An important limitation is our operationalization of serious falls. Our definition included those 306 
falls that cause a patient to present for health care. We therefore did not identify all falls. 307 
However, we likely identified those falls that were most concerning to the patient and provider. 308 
We were also unable to adjust for all potentially significant fall risk factors. Most importantly, we 309 
could not accurately identify those with peripheral neuropathy. Peripheral neuropathy is 310 
notoriously under assessed and thus administrative codes or even machine learning algorithms 311 
will not capture all those with the condition. Other conditions that we did not include (e.g 312 
Parkinson disease) are extremely rare among PLWH. Parkinson disease increases with age, 313 
reaching a prevalence of 2.6% in people aged 85-89 years in the generally population. No one 314 
in our sample was over 85 years of age. Furthermore, only 3% of the sample were women. 315 
Additional research is needed to explore models for serious fall risk factors that stratify by sex. 316 
In conclusion, our analysis suggests that use of specific medication classes, higher numbers of 317 
chronic medications, hazardous alcohol and ongoing substance use are potent risk factors for 318 
serious falls. Benzodiazepines and muscle relaxants are associated with increased risk of a 319 
serious fall among PLWH but not in uninfected comparators. Fall prevention programs that 320 
target the needs of PLWH will need to address the risk factors identified in this study. In addition 321 
to emphasizing exercise, balance, gait, strength training and polypharmacy, these programs will 322 
need to confront ongoing hazardous alcohol and illicit substance use and identify approaches to 323 
deprescribing that will balance the needs of this middle-aged population against their elevated 324 
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Table 1. Sample description by HIV status 











Mean age at baseline (years)† 54±9  55±9  
Mean age at time of fall or match 
(years)† 
57±10  58±9  
Race/ethnicity 
     White 
     Black 
     Hispanic 












Women 3%  4%  
Health Factors 
Smoking 
     Never 
     Current 


















BMI† 26±5 26±5 0.45 30±6 30±6 0.13 
Underweight (<18.5) 2% 2% 0.07 1.0% 0.74% 0.001 
Normal weight (18.5 – 25) 35% 36% 0.46 18% 16% <0.001 
Overweight (25-30) 30% 32% 0.09 31% 32% 0.03 
Obese (>30) 17% 17% 0.68 42% 42% 0.15 
Specific Medications 
Opioid 30% 18% <0.001 33% 22% <0.001 
Benzodiazepine 13% 14% <0.001 14% 10% <0.001 
Muscle relaxant 9% 5% <0.001 12% 9% <0.001 
Anticonvulsant 19% 11% <0.001 22% 14% <0.001 
Antihistamine 19% 13% <0.001 17% 14% <0.001 
Antiarrhythmics 3% 1% <0.001 3% 1% <0.001 
Antihypertensives 47% 44% 0.003 59% 56% <0.001 
Antithrombotics 6% 5% <0.001 8% 6% <0.001 
Nitrates 4% 2% <0.001 5% 3% <0.001 
Antipsychotics 11% 8% <0.001 14% 12% <0.001 
Atypical antidepressants 18% 13% <0.001 19% 14% <0.001 
MAO Inhibitors 0.03% 0.01% 0.45 0.08% 0.03% 0.03 
SNRI 4% 2% <0.001 4% 3% <0.001 
SSRI 20% 14% <0.001 22% 16% <0.001 
Tricyclic antidepressants 5% 3% <0.001 4% 3% 0.001 
Hypoglycemics 11% 9% <0.001 19% 16% <0.001 
Proton pump inhibitors 21% 15% <0.001 31% 24% <0.001 
Polypharmacy 
Medication count (with ART)† 10±7 8±6 <0.001 9±7 7±6 <0.001 
Medication count (without ART)† 8±6 6±5 <0.001 9±7 7±6 <0.001 
Substance Use 
Hazardous alcohol use (>=3 for 
women and >=4 for men) 
13% 9% <0.001 14% 11% <0.001 
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Illicit substance use 36% 27% <0.001 28% 20% <0.001 
Comorbidities 
VACS Index Score V2.0†  54±16 51±15 <0.001 34±11 32±10 <0.001 
Osteoarthritis 21% 15% <0.001 40% 35% <0.001 
HCV 30% 24% <0.001 16% 11% <0.001 
CNS diagnoses 
     Stroke 
     TIA 


























     COPD 




















     Hypertension 
     Coronary artery disease 

























Mental health diagnoses 
     Anxiety 
     Bipolar disorder 
     Major depression 
     Mild depression 
     Psychosis 












































On ART 79% 82% 0.10    
ART Classes (among those on ART 
Protease inhibitors (excluding 
RTV) 
37% 37% 0.71    
Nucleoside/nucleotide reverse 
transcriptase inhibitors 
69% 73% 0.01    
Non-nucleoside reverse 
transcriptase inhibitors 
33% 37% <0.001    
Integrase inhibitors 14% 12% 0.01    
Fusion inhibitors 2% 1% 0.10    
Boosters (RTV or cobicistat) 33% 33% 0.75    
Individual ART (among those on ART)‡ 
3TC 22% 24% 0.02    
Abacavir 13% 13% 0.94    
Tenofovir 49% 51% 0.09    
FTC 44% 46% 0.24    
Zidovudine 11% 13% 0.001    
Efavirenz 25% 29% <0.001    
Ritonavir 33% 33% 0.82    
Atazanavir 15% 16% 0.27    
Darunavir 9% 8% 0.07    
Lopinavir/ritonavir 9% 9% 0.69    




‡ ART used by <5% of the sample were excluded from the table. These include: didanosine, 
Maraviroc, enfuvirtide, nevirapine, rilpivirine, etravirine, zalcitabine, nelfinavir, fosamprenavir, 
indinavir tipranavir, saquinavir, cobicistat, dolutegravir, elvitegravir 
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Table 2. Multivariable associations with serious falls among PLWH and uninfected comparators 1 




CNS active medications 
     Benzodiazepines among PLWH 
     Benzodiazepines among uninfected 
     Muscle relaxants among PLWH 
     Muscle relaxants among uninfected 
     Opioids 
     Anticonvulsants 
     Antihistamines 
 
1.25 (1.12, 1.39) 
1.02 (0.95, 1.10) 
1.32 (1.14, 1.41) 
1.04 (0.96, 1.12) 
1.33 (1.27, 1.39) 
1.32 (1.25, 1.39) 










     Antithrombotics 
     Antiarrhythmics 
     Antihypertensives 
     Nitrates 
 
1.20 (1.11, 1.30) 
1.32 (1.16, 1.50) 
0.85 (0.81, 0.89) 






Mental health medications 
     SSRI 
     SNRI 
     Atypical antidepressants 
     MAOI 
     TCA 
     Antipsychotics 
 
1.22 (1.16, 1.28) 
1.16 (1.05, 1.29) 
1.04 (0.99, 1.10) 
2.37 (1.05, 5.33) 
0.95 (0.86, 1.05) 








Hypoglycemics 0.97 (0.91, 1.03) -1 
Proton pump inhibitors 1.06 (1.01, 1.11) 2 
Polypharmacy 
Medication count (excluding ART) 
(increments of 5) 
1.19 (1.16, 1.22) 14 
Substance use 
Hazardous alcohol use (AUDIT-C score 
>3 for women and >4 for men)  
1.32 (1.24, 1.39) 10 
Illicit substance use 1.36 (1.30, 1.42) 14 
Additional covariates 
VACS Index 2.0 (increments of 5) 1.06 (1.05, 1.06) 13 
 Body Mass Index     
     <18.5 
     18.5 – 25 
     25 – 30 
     > 30 
 
0.99 (0.84, 1.17) 
REF 
1.00 (0.95, 1.06) 






Smoking was not included in the model as it is collinear with VACS Index Score 2.0 2 
The matching variable, HIV, was included in the model but is not shown here 3 
Abbreviations: CNS: central nervous system; SSRI: selective serotonin reuptake inhibitors; SNRI: 4 
serotonin/norepinephrine reuptake inhibitors; MAOI: monoamine oxidase inhibitors; TCA: tricyclic 5 
















Figure 2. Associations stratified by HIV status 18 
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P for interaction =0·002




Table. Medications included in the different drug classes 21 




































































































































































































































































































































































Proton pump inhibitors ESOMEPRAZOLE 
LANSOPRAZOLE 
LANSOPRAZOLE/NAPROXEN 
OMEPRAZOLE 
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OMEPRAZOLE/SODIUM 
BICARBONATE 
PANTOPRAZOLE 
RABEPRAZOLE 
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